Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Search conditions, treatments, research reviews and articles. Press Enter to see all results, Esc to close.
Blog
October 24, 2026
No. There is no cure for glaucoma, and vision lost to it does not come back. But early treatment can often stop the damage from getting worse and protect the vision you still have. In a few situations the cause itself can be removed: laser or lens surgery can open a closed drainage angle, surgery in babies can control congenital glaucoma, and stopping a steroid can bring pressure back down. This page explains what treatment can and cannot do, what studies of “reversal” actually show, and where research on protecting and regrowing the optic nerve stands in 2026.
For the condition as a whole, including the types, symptoms, who is at risk, how it is diagnosed, today’s treatments and the trials testing nerve protection, read our glaucoma guide.
Glaucoma damages the retinal ganglion cells, the nerve cells whose long fibers bundle together to form the optic nerve. Like other nerve cells in the brain and spinal cord, they have very limited ability to regrow once they die. That is why the National Eye Institute says treatment “won’t undo any damage to your vision”, and why lost side vision does not return.
The only proven way to protect the remaining cells is to lower eye pressure, with drops, laser or surgery. That lowers the risk of further damage but does not remove the underlying vulnerability of the optic nerve, so treatment and monitoring usually continue for life. MedlinePlus puts it simply: “There is no cure, but glaucoma can usually be controlled.”
Lowering pressure clearly slows glaucoma. In the United Kingdom Glaucoma Treatment Study, 15.2% of people using latanoprost drops had visual field loss after two years, against 25.6% of people using a dummy drop. In the Early Manifest Glaucoma Trial, treatment cut the share whose glaucoma worsened over about six years from 62% to 45%. For people with high eye pressure but no damage yet, the Ocular Hypertension Treatment Study found that drops halved the chance of developing glaucoma over five years (4.4% against 9.5%).
The aim of treatment is to keep enough vision for the rest of your life. Our guides to glaucoma eye drops and glaucoma surgery and laser explain the options.
When the iris blocks the drainage angle, laser peripheral iridotomy is the treatment of choice: it makes a small hole in the iris that relieves the block and helps prevent future attacks. Removing the eye’s natural lens can widen the angle further, and in the EAGLE trial, lens removal worked better than laser iridotomy in people aged 50 or older. This fixes the blockage, not the glaucoma itself. Optic nerve damage that has already happened stays, and a preventive iridotomy, while it greatly lowers the risk of an attack, does not guarantee the eye stays healthy. Some eyes still develop raised pressure or chronic angle closure later: about 1 in 10 fellow eyes over about four years in a Singapore series, and about half over about six years in a small Italian series of people whose first eye already had chronic angle-closure glaucoma. So checks continue for life. Our guide to angle-closure glaucoma covers this in detail.
Glaucoma present from birth affects about 1 in 10,000 babies in the United States. The National Eye Institute says surgery works very well, and babies who have it early enough usually avoid permanent vision loss. Reported success rates for goniotomy, a common first operation, range from 70% to 90%. The condition can still come back, so children need checks for life.
Steroid medicines, especially eye drops, raise eye pressure in some people. After topical steroids are stopped, pressure often returns toward normal within a few weeks. Any optic nerve damage already done is permanent. Never stop a steroid on your own: if it is treating serious inflammation or another illness, your doctors need to plan the change together.
A very swollen or leaking cataract can cause a painful form of glaucoma, and removing the lens is the only definitive treatment. More generally, when glaucoma is caused by another condition, treating that condition may help, although other treatment is often still needed. See glaucoma vs cataracts for how the two interact.
Ocular hypertension means pressure above 21 mmHg with a healthy optic nerve and visual field. It is a risk factor, not glaucoma, and many people with it never develop glaucoma. If you were told your pressure is high but your nerve is healthy, read our guide to high eye pressure (ocular hypertension).
Mostly no, but the picture is more nuanced than it used to be. Several studies show partial improvement after pressure is lowered a lot:
These findings suggest that ganglion cells that are struggling but still alive can work better once pressure is controlled. They do not show that dead cells come back, or that glaucoma can be cured. The National Eye Institute’s summary still holds: once glaucoma damages the optic nerve, lost vision cannot be restored.
Nicotinamide is a form of vitamin B3 that may help ganglion cells meet their energy needs. In a crossover trial of 57 people taking nicotinamide for 12 weeks (1.5 grams a day, then 3 grams a day), a measure of inner retinal function improved by 14.8%, with only a trend toward better visual fields. A 2022 trial of nicotinamide with pyruvate found more improving visual field points than placebo over about two months, but no change in the main field index. A 2026 trial in normal-tension glaucoma improved electrical retinal responses but not visual fields. A 2026 review of the human studies concluded the evidence is not yet enough to support routine high-dose use. Four large trials are now under way:
| Trial | Where it stands |
|---|---|
| NAMinG (United Kingdom) | Phase 3, placebo-controlled; 378 people randomised and recruitment closed in April 2026. The trial is due to finish in November 2028. |
| TGNT (Sweden, with partners) | Placebo-controlled, 660 people planned; main outcome is visual field progression at two years. Estimated completion December 2026, though the registry record has not been updated since 2023. |
| TAMING (Singapore) | Phase 3, 520 people planned, two years of nicotinamide or placebo. Expected to complete in 2028. |
| Nicotinamide plus pyruvate (Columbia University, United States) | Phase 2/3, about 21 months of treatment; no longer recruiting. Expected to complete in 2028. |
The doses in these trials are far higher than you get from food. Do not start high-dose nicotinamide without talking to your eye doctor and your physician.
In the Low-Pressure Glaucoma Treatment Study, fewer people using brimonidine drops had visual field progression than those using timolol (9.1% against 39.2%), but many more stopped brimonidine because of side effects, and a Cochrane review rated the evidence as very low certainty. Oral memantine, once a promising candidate, failed to slow glaucoma in two phase 3 trials of 2,298 people. Our glaucoma guide lists other treatments in clinical trials, such as citicoline drops and implanted cell therapies.
No stem cell, gene or regenerative therapy is approved by the FDA for glaucoma. Replacing lost ganglion cells and getting them to reconnect to the brain is still at the laboratory stage, and the first human studies of related approaches, such as a one-time epigenetic therapy that began a phase 1 safety trial in 2026, are only testing safety. The FDA warns that unapproved “regenerative” products, often sold by clinics, have caused harm, including blindness.
Searches such as “how I cured my glaucoma” or “reverse glaucoma naturally in two weeks” lead to stories and products that promise what no treatment has shown. In September 2023, the FDA sent warning letters to eight companies selling unapproved eye products, including some marketed for glaucoma, noting that such products may cause people to delay or stop treatment that works. Supplements, exercises and eye drops sold as cures cannot regrow the optic nerve. Exercise and a healthy diet support overall health, and our guide to lowering eye pressure naturally explains what the evidence does and does not support. None of it replaces pressure-lowering treatment.
Netra Restoration Therapy (NRT) at Netra Eye Institute does not cure glaucoma, lower eye pressure or regrow the optic nerve, and it must never replace pressure-lowering treatment. Once glaucoma is medically controlled, some people still struggle with scanning, reading or getting around because of field loss that has already happened. A functional assessment can target those tasks and coordinate with low-vision care. Any improvement in a task is not a sign that glaucoma has been reversed.
Learn about Netra Restoration Therapy, Netra Eye Institute’s approach and low-vision rehabilitation.
No. There is no cure for glaucoma yet. Treatment with drops, laser or surgery lowers eye pressure and can often stop the damage from getting worse, but it cannot undo damage already done, so most people need treatment and checks for life.
Vision lost to glaucoma does not come back. After large pressure drops, the optic nerve can look less cupped and some test results can improve slightly, especially in early disease, but these are small, partial gains rather than a reversal.
It is not curable, but it is very treatable when caught early. Finding it before much damage has happened gives treatment the best chance of protecting your sight for life, which is why regular eye exams matter even when your vision seems fine.
It can’t be, with current treatment. The closest thing to a permanent fix is in angle-closure glaucoma, where laser iridotomy or lens surgery can remove the blockage, and in congenital glaucoma, where early surgery often controls the pressure. Even then, the eye needs lifelong monitoring.
No. Laser lowers eye pressure, and laser iridotomy can stop angle-closure attacks, but neither cures glaucoma. The Glaucoma Research Foundation says plainly that SLT “is not a cure”, and the National Eye Institute notes its effect wears off over time, so some people need it again or need drops as well.
No. Drops control eye pressure while you use them. If you stop, the pressure goes back up. They protect vision but do not cure the disease.
No natural remedy has been shown to reverse glaucoma or regrow the optic nerve. Regular exercise may lower eye pressure slightly, and a healthy diet supports general health, but neither replaces prescribed treatment.
Not in the sense of restoring lost vision. The nearest advances are nerve-protection treatments such as nicotinamide, with large trials due to finish between late 2026 and 2028, and new pressure-lowering drugs and implants. Regrowing the optic nerve is still in early research.
No. High-dose nicotinamide (a form of vitamin B3) improved some short-term measures of retinal function in small trials, but it has not been shown to stop glaucoma or restore vision. Large trials are under way, and a 2026 review concluded the evidence is not yet strong enough to support routine high-dose use.
Glaucoma can’t yet be cured or reversed, but it can usually be controlled. Lowering eye pressure is proven to slow vision loss, a few causes can be removed outright, and research into protecting the optic nerve is further along than ever. The most useful thing you can do today is find glaucoma early and keep up the treatment and checks that protect the vision you have.
Medical Disclaimer: This article provides general education and is not medical advice, diagnosis or treatment. Glaucoma treatment must be planned and monitored by a licensed eye-care professional. Do not stop prescribed drops, steroids or other treatment to try an unproven remedy. Sudden eye pain, redness, blurred vision or halos with headache, nausea or vomiting requires emergency care. NRT does not treat glaucoma and must never delay or replace pressure-lowering care.
